KoBioLabs Past Earnings Performance
Past criteria checks 0/6
KoBioLabs has been growing earnings at an average annual rate of 36%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 86.4% per year.
Key information
36.0%
Earnings growth rate
62.4%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 86.4% |
| Return on equity | -20.1% |
| Net Margin | -21.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Does KoBioLabs (KOSDAQ:348150) Have A Healthy Balance Sheet?
Sep 06
Cautious Investors Not Rewarding KoBioLabs, Inc's (KOSDAQ:348150) Performance Completely
Jul 12We're Not Worried About KoBioLabsInc's (KOSDAQ:348150) Cash Burn
Apr 15What Type Of Shareholders Own The Most Number of KoBioLabs,Inc (KOSDAQ:348150) Shares?
Feb 18Revenue & Expenses Breakdown
How KoBioLabs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 52,081 | -11,096 | 36,658 | 10,739 |
| 31 Mar 24 | 40,321 | -12,608 | 31,240 | 12,333 |
| 31 Dec 23 | 33,138 | -13,853 | 27,321 | 14,262 |
| 30 Sep 23 | 29,303 | -16,091 | 24,856 | 13,506 |
| 30 Jun 23 | 24,119 | -17,122 | 21,712 | 14,838 |
| 31 Mar 23 | 18,249 | -21,739 | 17,813 | 14,593 |
| 31 Dec 22 | 11,606 | -21,921 | 13,675 | 14,198 |
| 30 Sep 22 | 5,809 | -17,940 | 9,118 | 13,575 |
| 30 Jun 22 | 3,973 | -17,851 | 7,223 | 12,766 |
| 31 Mar 22 | 3,233 | -16,061 | 6,003 | 13,447 |
| 31 Dec 21 | 2,893 | -15,382 | 5,580 | 12,496 |
| 30 Sep 21 | 4,936 | -17,289 | 6,845 | 11,686 |
| 30 Jun 21 | 5,219 | -15,509 | 6,792 | 10,413 |
| 31 Mar 21 | 5,067 | -12,945 | 6,593 | 9,171 |
| 31 Dec 20 | 4,591 | -55,072 | 5,894 | 8,882 |
| 30 Sep 20 | 1,752 | -51,005 | 4,178 | 7,777 |
| 30 Jun 20 | 945 | -50,232 | 3,912 | 7,578 |
| 31 Mar 20 | 685 | -68,745 | 3,513 | 5,790 |
| 31 Dec 19 | 577 | -44,067 | 3,153 | 4,319 |
| 31 Dec 18 | 64 | -8,382 | 1,523 | 717 |
Quality Earnings: A348150 is currently unprofitable.
Growing Profit Margin: A348150 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A348150 is unprofitable, but has reduced losses over the past 5 years at a rate of 36% per year.
Accelerating Growth: Unable to compare A348150's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A348150 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).
Return on Equity
High ROE: A348150 has a negative Return on Equity (-20.06%), as it is currently unprofitable.